drugset / Trial / NCT02520518

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

NCT02520518

Phase 2 Terminated 9 enrolled Christopher Bell AstraZeneca · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.

Timeline

Start
2015-08
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral

Indications

No indication recorded.